- Home
- CTO vs FDMT Comparison
CTO vs FDMT Comparison
Compare CTO & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | FDMT |
|---|---|---|
| Founded | 1902 | 2013 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.1M | 479.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CTO | FDMT |
|---|---|---|
| Price | $20.23 | $8.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $21.50 | ★ $31.71 |
| AVG Volume (30 Days) | 163.6K | ★ 652.3K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.72% | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $2.76 | $70.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $15.07 | $3.03 |
| 52 Week High | $20.25 | $12.34 |
Technical Indicators
Market Signals| Indicator | CTO | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 66.86 | 40.43 |
| Support Level | $19.22 | $8.25 |
| Resistance Level | N/A | $10.70 |
| Average True Range (ATR) | 0.33 | 0.49 |
| MACD | 0.03 | -0.14 |
| Stochastic Oscillator | 72.39 | 4.95 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).